HIF-PH inhibitors for anaemia
Oral drugs such as roxadustat for anaemia of kidney disease.
Key point
HIF-PHIs such as roxadustat are reserved for non-dialysis CKD when erythropoiesis-stimulating agents are unsuitable, given potential risks and limited long-term data.
From: Position statement of the SEN Anemia Working Group: A critical and contextualized adaptation of the KDIGO 2026 anemia guidelines to the Spanish setting (Nefrologia (Engl Ed), 2026 Aug-Sep) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 3, 7, 4, 9, 9.
New guidelines and consensus this year
All papers from the last 12 months
149 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Efficacy and safety of roxadustat for the treatment of renal anemia in patients undergoing peritoneal dialysis: a systematic review and meta-analysisRen Fail2026 DecPMID 42838123Meta-analysisSystematic review
- Initial side effects of roxadustat on thyroid function in patients undergoing hemodialysisRen Fail2026 DecPMID 42820476
- Association Between Perioperative Daprodustat Use and Early Posttransplant Graft Function in Living Donor Kidney Transplantation: A Propensity Score-Matched Retrospective StudyCurr Ther Res Clin Exp2026 DecPMID 42472023
- Roxadustat attenuates contrast-induced acute kidney injury potentially mediated via the Nrf2/HO-1 signaling pathwayRen Fail2026 DecPMID 42161900
- Efficacy and safety of prolyl hydroxylase inhibitors for anemia in chronic kidney disease: a network meta-analysisRen Fail2026 DecPMID 41633330
- Epicatechin alleviates ulcerative colitis by restoring intestinal mucosa via regulating the NCR(+)ILC3 cell countsPhytomedicine2026 NovPMID 42727461
- Roxadustat and incidence of peritoneal dialysis-associated peritonitis: a propensity score-matched cohort studyClin Exp Nephrol2026 NovPMID 42573958
- Detection and confirmation of hypoxia-inducible factor activating agents in equine plasma and urine by liquid chromatography coupled to mass spectrometryJ Chromatogr A2026 Oct 11PMID 42594630
- Impact of HIF-prolyl hydroxylase inhibitors on VEGF expression and vascular adverse events in chronic kidney disease: a meta-analysis of 34 randomized controlled trialsJ Nephrol2026 Oct 10PMID 42488997Meta-analysis
- Acute Kidney Injury and Heart Failure Risk with Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors: A Network Meta-AnalysisClin Pharmacol Ther2026 Oct 5PMID 42834713Review
More nephrology trends
All specialties →Complement inhibitors in kidney disease
Iptacopan, avacopan and other complement inhibitors in glomerular disease.
Key point: Complement inhibitors had no overall effectiveness or safety advantage over plasma therapy in atypical hemolytic uremic syndrome, except lower relapse rates.
APOL1 kidney disease
Kidney disease linked to APOL1 gene variants.
Home dialysis
Home haemodialysis and peritoneal dialysis.
Key point: Core interventions to reduce PD-related infections focus on surveillance, standardized staff and patient training, infection prevention assessments, and antimicrobial prophylaxis.
Race-free eGFR
Kidney function equations without a race coefficient.
Pig kidney xenotransplantation
Transplanting genetically modified pig kidneys into humans.
Potassium binders
Patiromer and sodium zirconium cyclosilicate for hyperkalaemia.
Key point: In type 2 diabetes with hyperkalemia, sodium zirconium cyclosilicate did not demonstrate noninferiority to potassium-restricted diet for achieving normokalemia.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
roxadustat[tiab] OR daprodustat[tiab] OR vadadustat[tiab] OR "HIF-PH"[tiab] OR "HIF prolyl hydroxylase"[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.